As of November 6, 2026, Larimar Therapeutics, Inc. is a publicly traded company (Nasdaq: LRMR). The largest holder reporting an active stake on Schedule 13D is James E. Flynn, at 34.41%. No bankruptcy or receivership appears in its SEC Form 8-K filings. Passive holders reporting on Schedule 13G include Blue Owl Capital Holdings LP (9.99%) (Schedule 13D/A, March 2, 2026).
Is this your company?
About to sign with, pay or invest in Larimar Therapeutics, Inc.? See the free Snapshot first.
Free to see. No signup.
Is Larimar Therapeutics, Inc. a real, registered company?
- Larimar Therapeutics, Inc. files with the SEC under CIK 1374690 (its SEC filings).
- Its shares are listed under the ticker LRMR on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in Bala Cynwyd, Pennsylvania, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under Larimar Therapeutics, Inc. in our court records and SEC 8-K records (as of 2026-11-06).
- Leadership changes: the latest reported is John B. Harlow, Chief Operating Officer (Form 8-K filed 2026-09-29). Check you are dealing with the people now in charge.
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Blue Owl Capital Holdings LP (filed 2026-05-14).
Who are Larimar Therapeutics, Inc.'s owners and officers?
Larimar Therapeutics, Inc.: incorporated in Delaware; business address in Bala Cynwyd, Pennsylvania; industry Pharmaceutical Preparations (Form D, 2026-09-29).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-05-14 | Blue Owl Capital Holdings LP | 9.99% |
| Schedule 13G/A, 2026-04-30 | Millennium Management LLC | 3.5% |
| Schedule 13D/A, 2026-03-02 | James E. Flynn | 34.41% |
| Schedule 13G/A, 2026-02-17 | Ra Capital Management, L.P. | 0% |
| Schedule 13G/A, 2026-02-12 | Blue Owl Capital Holdings LP | 9.99% |
| Schedule 13G/A, 2025-11-06 | Millennium Management LLC | 5.8% |
| Schedule 13G, 2025-08-29 | Opaleye Management, Inc. | 4.8% |
| Schedule 13G/A, 2025-08-14 | Janus Henderson Group PLC | 0% |
| Schedule 13D/A, 2025-07-31 | James E. Flynn | 35.81% |
Questions about who owns Larimar Therapeutics, Inc.
Who owns Larimar Therapeutics, Inc.?
On this page, 2 holders' latest ownership filings report 5% or more of Larimar Therapeutics, Inc.: James E. Flynn (34.41%, Schedule 13D/A, filed 2026-03-02) and Blue Owl Capital Holdings LP (9.99%, Schedule 13G/A, filed 2026-05-14).
Who are the largest shareholders of Larimar Therapeutics, Inc.?
By the share each holder's latest filing reports, the largest holders of Larimar Therapeutics, Inc. on this page are James E. Flynn (34.41%) and Blue Owl Capital Holdings LP (9.99%).
When did James E. Flynn buy into Larimar Therapeutics, Inc.?
The filings give report dates, not purchase dates. The earliest filing from James E. Flynn on this page is the Schedule 13D/A, filed 2025-07-31, reporting 35.81%; its latest, Schedule 13D/A filed 2026-03-02, reports 34.41%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 9 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Larimar Therapeutics, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Larimar Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Larimar Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
12 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
| Filed | Person | Role | Change | Effective |
|---|---|---|---|---|
| Form 8-K, 2026-09-29 | John B. Harlow | Chief Operating Officer | appointed | 2026-09-29 |
Which insiders own Larimar Therapeutics, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- Deerfield Management Company, L.P., a director and 10% owner: 35,606,974 shares (34.3% of shares outstanding), held indirectly through Through Deerfield Private Design Fund III, L.P. and 2 other Through Deerfield funds, on a joint filing (Form 4, 2026-03-02).
- Deerfield Partners, L.P., a director and 10% owner: 35,606,974 shares (34.3% of shares outstanding), held indirectly through Through Deerfield Private Design Fund III, L.P. and 2 other Through Deerfield funds, on a joint filing (Form 4, 2026-03-02).
- Deerfield Mgmt L.P., a director and 10% owner: 35,606,974 shares (34.3% of shares outstanding), held indirectly through Through Deerfield Private Design Fund III, L.P. and 2 other Through Deerfield funds, on a joint filing (Form 4, 2026-03-02).
- , L.P., a director and 10% owner: 35,606,974 shares (34.3% of shares outstanding), held indirectly through Through Deerfield Private Design Fund III, L.P. and 2 other Through Deerfield funds, on a joint filing (Form 4, 2026-03-02).
- Deerfield Private Design Fund IV, L.P., a director and 10% owner: 35,606,974 shares (34.3% of shares outstanding), held indirectly through Through Deerfield Private Design Fund III, L.P. and 2 other Through Deerfield funds, on a joint filing (Form 4, 2026-03-02).
Shares outstanding: 103,882,937 as of 2026-08-02, from the company's latest SEC cover page.
How much has Larimar Therapeutics, Inc. raised?
No fundraising or offering filing from Larimar Therapeutics, Inc. is on file with us.
Keep reading
More on Larimar Therapeutics, Inc. and the records around it.
Larimar Therapeutics, Inc. elsewhere on the record
- Leadership changes Sep 2026
- 5%+ stake filings May 2026
Companies that share a holder
- Blue Owl Capital Holdings LP also filed stake reports on 10 other companies: Context Therapeutics Inc. (Aug 2026), enGene Therapeutics Inc. (Aug 2026), Aktis Oncology, Inc. (May 2026)
- Opaleye Management, Inc. also filed stake reports on 12 other companies: Codexis, Inc. (Nov 2026), Gossamer Bio, Inc. (Nov 2026), Pasithea Therapeutics Corp. (Nov 2026)
- Deerfield Private Design Fund III, L.P. also filed stake reports on 19 other companies: Climb Bio, Inc. (Oct 2026), Cogent Biosciences, Inc. (Aug 2026), Enhabit, Inc. (Aug 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/larimar-therapeutics